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ABSTRACT
Non-communicable diseases including cardiovascular diseases (CVD) and diabetes have become the leading causes of mortality and morbidity among Palestinians. A low level of highdensity lipoproteins (HDL) is a major modifiable risk factor for CVD. This study aimed to determine the prevalence and risk factors associated with low HDL among adult Palestinians. A specific
objective was to establish the prevalence of metabolic syndrome among adult Palestinians. A crosssectional study was conducted in the West Bank from 2018 to 2019 to achieve study objectives. A
total of 1086 participants (526[48.3%] women and 560[51.7%] men) aged 18-65 years were included in this study. National Cholesterol Education Program (NCEP-ATP-III) criterion was used
to define metabolic syndrome. Low HDL-cholesterol was highly prevalent among Palestinians
(560[51.6%]) with no differences between men (288[51.3%]) and women (272[51.8%]) (p value=0.876). Levels of HDL ranged from 13.8 to 91.4 milligrams per deciliter (mg/dl) in men with a
mean level of 40.53±10.48 mg/dl and from 21.0 to 98.6 mg/dl in women with a mean level of
50.30±12.5mg/dl. According to NCEP-ATP definition, metabolic syndrome was highly prevalent
among adult Palestinians (366[33.8%]) with no differences between men (192[34.2%]) and women
(174[33.2%]) (p value=0.707). The univariate analysis revealed that metabolic syndrome (Odd ratio (OR), 10.79, 95% Confidence Interval (CI) (7.78-14.9)) and all increased metabolic abnormalities including triglycerides (OR,4.284, 95%CI (3.23-5.681)), fasting blood sugar (OR, 2.145,
95%CI (1.561-2.949)), blood pressure (OR, 2.133, 95%CI (1.671-2.272)), waist circumferences
(OR, 2.506, 95%CI (1.937-3.242)), and obesity (OR, 2.176, 95%CI (1.685-2.809)) were significantly associated with low HDL (p value <0.001). The univariate analysis revealed also a significant association between low HDL and being married (OR, 2.183, 95%CI (1.695-2.817)), smoking
(OR, 1.704, 95%CI (1.269-2.289)), and exposure to pesticides (OR, 1.702, 95%CI (11.164-2.489))
(p value <0.001). Logistic-Regression Model identified only increased triglycerides (OR, 3.341,
95%CI (2.165-5.155), p value <0.001)) and increased waist circumferences (OR, 1.841, 95%CI
(1.200-2.825), p value=0.005)) to be significantly associated with low HDL. Although low HDL
was highly prevalent among overweight and obese (412[38.08%]), it was highly prevalent among
underweight and normal weight adults (147 [13.59%]). Low HDL was highly prevalent among
adult Palestinians with dyslipidemia and central obesity being the most associated abnormalities.
Action should be taken to prevent the rise of preventable non-communicable diseases. If no action
is taken to reduce these diseases, they will become an increasing burden for the Palestinian health
system.
Keywords: Cardiovascular Disease; Metabolic Syndrome; Low HDL; Central Obesity;
Dyslipidemia, Palestinians, NCEP-ATP III.
moves excess cholesterol from atherosclerotINTRODUCTION
ic plaques and has anti-inflammatory and
High-density lipoproteins (HDL) are enanti-oxidative properties that protect the cardogenous nanoparticles involved in the
diovascular system [2]. Circulating HDLtransport and metabolism of cholesterol,
cholesterol also transports endogenous prophospholipids, and triglycerides [1]. It re-
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teins, vitamins, hormones, and microRNA to
various organs [1].
The reference range of HDL levels is 4050 milligram per deciliter (mg/dl) in men and
50-60 mg/dl in women [3]. Low levels of
HDL, or hypoalphalipoproteinemia (HA), has
no clear-cut definition and includes a variety
of conditions, ranging from mild to severe, in
which concentrations of alpha lipoproteins or
HDL are reduced [4]. An arbitrary cutoff
used frequently in the old literature includes a
HDL level that falls within the 10th percentile
of HDL levels [4]. The US National Cholesterol Education Program (NCEP) Adult
Treatment Panel III (ATP III) redefined the
HDL level that constitutes a formal CHD risk
factor. The minimum desirable level was
raised from 35 to 40 mg/dL for both men and
women [5]. For metabolic syndrome (MetS)
in which multiple mild abnormalities in lipids, waist size (abdominal circumference),
blood pressure, and blood sugar increase the
risk of CAD, the designated HDL cholesterol
levels that contribute to the syndrome are
sex-specific [6]. For men, a high-risk HDL
cholesterol level is less than 40 mg/dl, but for
women, the high-risk HDL cholesterol level
is less than 50 mg/dl [7, 8].
Several epidemiological and genetic
studies confirmed the association between
elevated HDL levels and protection against
atherogenesis [9, 10]. On the other hand, a
low level of serum HDL cholesterol was established to be an independent risk factor for
coronary artery disease (CAD) [11, 12]. It is
shown to be a key component in the prediction of cardiovascular disease (CVD) [13,
14]. Moreover, there is evidence that low
HDL-cholesterol is in association with
metabolic syndrome and type 2 diabetes
patients [15]. It has been estimated that more
than 80% of all CVD mortality occurs in developing countries [16]. Moreover, emerging
data from developing countries suggest that
low HDL may be the most common lipid
abnormality observed in these societies [17].
Many risk factors have influence on
HDL levels. The etiology of HDL deficiency
ranges from secondary factors to specific genetic mutations, such as Tangier disease and
fish-eye disease [18, 19]. Secondary factors
such as gender, age, obesity, smoking,
alcohol, diet, starvation, stress, physical

activity, drugs (e.g., steroids, statins, and
fibrates) or other metabolic disorders (e.g.,
insulin resistance and liver disease) have
been shown to influence HDL levels in
numerous epidemiological studies [20-28].
Diseases that affect levels of HDL include
hypertriglyceridemia, uncontrolled diabetes
mellitus (DM), metabolic syndrome and
chronic renal failure [29-31]. Environmental
influences are known to regulate HDL cholesterol levels; however, genetic factors are
also known to be important [17]. Levels of
HDL appear to be under a strong inherited
basis, with heritability estimates of 40–60%
[32-34]. Genetic variants may also contribute
to inter-individual variability in HDL response to environmental factors [17]. Genes
are modulated by several non-modifiable factors such as gender and age and modifiable
factors, such as diet, smoking, obesity, and
alcohol intake among many others.
Cardiovascular disease has become the
most common leading cause of mortality
among Palestinians. Few studies were conducted to describe metabolic syndrome in
vulnerable groups had described the percentages of low HDL among Palestinians. Low
HDL percentages had ranged from 28.6%
among refugee women in the West Bank [35]
to 74.7% among overweight and obese young
adults [36]. Low HDL-level was the second
most common component of MetS after central obesity among overweight and obese
subjects [36-39]. Factors behind this low
HDL in the Palestinian population were not
investigated.
To the authors' best knowledge, no studies were conducted to establish the prevalence of low HDL cholesterol and to investigate its associated risk factors in Palestinians.
Such studies are important in drawing protective policies. Large-scale prospective studies
have indicated that each 1 mg/dl increase in
HDL is associated with a two to three percent
decrease in the risk of CAD in men and
women, respectively [40]. This study aimed
to determine the prevalence of low HDL and
the risk factors associated with it among the
adult population aged 18-65 years in the
West Bank. A specific objective was to determine levels of low HDL as well as the association between low HDL and lifestyle and
metabolic abnormalities using the National
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Cholesterol Education Program (NCEP-ATP
III) criterion.
METHODS
Study design, population, and sampling
technique
A cross-sectional study was conducted in
the north of the West Bank from 2018 to
2019. There were 296058 adults in the north
of the West Bank aged >18 years (50.9%
males and 49.1% females) [41].Ten health
care clinics distributed in the north of the
West Bank were chosen randomly to recruit
1384 subjects. Apparently healthy subjects
aged 18-65 years who attend health care clinics in the north of the West Bank were recruited during the study period. To make sure
that the subjects were healthy, they were interviewed and asked if they had diseases,
types of medications they take regularly, if
they had any surgery in the last year, if they
had health care files in the health care clinic,
the reason for coming to health care clinics,
and if they had certain diseases or conditions
as explained in the exclusion criteria. Every
third apparently healthy subject was chosen
to participate in the study and was interviewed for personal, socio-demographic, and
lifestyle questions. The subject was also invited to give blood samples after fasting for
12 hours. Subjects with hypo- or hyperthyroidism, Cushing syndrome, epilepsy, or who
was taking regular medications other than
anti-diabetic or anti-hyperlipidemia medications or refused to give a blood sample were
excluded.
Blood analysis, measurement tools accuracy
and precision assessment
The National Cholesterol Education Program (NCEP-ATP III) criterion was used to
diagnose metabolic syndrome in this study.
Briefly, NCEP-ATP III proposed that the
individual must have at least three of the following cardiovascular risk factors to be diagnosed with MetS: Raised fasting blood glucose ≥110 milligrams per deciliter, raised
blood pressure: systolic BP ≥130 or diastolic
BP ≥85 millimeter of mercury (mm Hg),
raised triglycerides ≥ 150 (mg/dl), low HDL
cholesterol (HDL) (men <40 milligrams per
deciliter, women <50mg/dl, and increased
waist circumference ≥ 102 centimeters in
men or ≥ 88 centimeters in women. Blood

analysis was carried out in An-Najah National Hospital Laboratories. Blood samples were
collected and analyzed for blood sugar, triglycerides, and HDL using “Roche Chemistry Analyzer Cobas C 50.1). Accuracy and
precision of both anthropometric tools and
the questionnaire were assessed. Interviews
were conducted to avoid possible language
and literacy issues. The diagnostic criteria,
anthropometrics, and blood pressure measurements, venous blood collection and biochemical analysis, and measurement tools
accuracy and precision assessment were used
and published in previous works [36, 39, 42].
Current substance user for tobacco or alcohol
is a substance user who has used the substance at least once during the past 30 days.
Exposed to pesticides is any participant who
was exposed to pesticides through his occupation such as farmers.
Data analysis
Descriptive statistics were computed to
assess the personal characteristics of the participants. Univariate analysis was conducted
using a Chi-square test with an odds ratio
(OR) calculated for risk factors. Multivariate
logistic regression was performed for variables found to be significant in univariate
analysis. A P-value of <0.05 was considered
to indicate statistical significance and a confidence interval was set at 95%. Statistical
Product and Service Solutions (SPSS) (version 22, IBM Corporation) was used for data
entry and analysis.
Ethics
Ethical approval was obtained from Institutional Review Board "IRB" at An-Najah
National University in Palestine and additional approvals were obtained from the Palestinian Ministry of Health before research
conduction. The study was carried out following the ethical standards, Declarations of
Helsinki. A consent form was obtained from
each participant prior to participation. All
participants were assured that all data will be
confidential and available for the researcher
only. The blood tests were free of charge.
RESULTS
General characteristics
The total number of participants in this
study was 1086 (526[48.3%] women and
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560[51.7%] men) with a response rate of
80.2%. Six hundred and ninety-one (63.4%)
of them aged 18-40 years, 707(65.3%) were
overweight and obese,388(35.9%) were singles, 400(36.8%) were urban, 609(56.1%)
were rural, 77(7.1%) were refugees,
239(22.9%) were current smokers and the
duration of smoking ranged from around one
year to 53 years, 7(0.7%) were current alcohol users,520( 48%) were employed, 180
(16.6%) were students, 129(11.9%) were using pesticides in their work, 80(7.4%) walk
every day for two hours or more, 789(72.2%)
of them sleep for eight hours or more per
day, and 365(33.7%) sit in front of televisions or computers more than or equal to four
hours per day (Table 1).
Table (1): Socio-demographic, life-style,
characteristics of respondents.
Gender
n (%)
Male
560(51.7)
Female
526(48.3)
Age groups
18-40 years
691(63.4)
41-65 years
391(36.4)
Smoking tobacco; cigarettes or water pipes
Current smoker
239
(22.9)
Ex-smoker
206(19.0)
Alcohol intake
Current user
7(0.7)
Ex-user
14(1.3)
Marital status
Single
388(35.9)
Married
681(62.9)
Divorced or widow
13(1.2)
BMI
≥25
707(65.3)
<25
375(34.7)
Work and physical activity
Employed
520(48.0)
Unemployed
382(35.2)
Students
180(16.6)
Occupational exposure to pesti- 129(11.9)
cides
Sleep >8 hours/ day
789(72.2)
Walk ≥2 hours/day
80(7.4)
Regular physical activity ≥5 121(11.2)

Gender
times/week
Long sitting ≥4hours/day (e.g. in
front of televisions or computer)
Locality
City
Village
Camp

n (%)
365(33.7)

400(36.8)
609(56.1)
77(7.1)

Prevalence
of
metabolic
syndrome,
metabolic abnormalities, and levels of HDL
according to NCEP-ATPIII definition
Obesity was highly prevalent among
adult Palestinians (706[65.2%]) with no significant
differences
between
men
(374[67.1%]) and women (332[63.2%]) (p
value= 0.182) (Table2). According to NCEPATP definition, metabolic syndrome was
highly prevalent among adult Palestinians
(366[33.8%]) with no significant differences
between men (192[34.2%]) and women
(174[33.2%]) (p value= 0.707). The most
prevalent metabolic abnormalities were low
HDL (560[51.6%]) with no differences between men (288[51.3%]) and women
(272[51.8%]) (p value= 0.876), followed by
increased blood pressure (494[45.5%]) with
significant increase among men (281[50.1%])
compared to women (216[40.6%]) (p value=
0.002), and increased waist circumferences
(390[35.9%]) with significant increase in
women (233[42.3%]) compared to men
(167[29.8%]) (p value <0.001), and increased
triglycerides (349[32.2%]) with significant
increase in men (220[39.3%]) compared to
women (129[24.6%]) (p value <0.001). The
least prevalent metabolic abnormality was
increased fasting blood sugar (206[19%])
with no significant differences between men
(110[19.6%]) and women (96[18.3%]) (p
value= 0.578) (Table 2). Levels of HDL
ranged from 13.8 to 91.4 milligrams per deciliter (mg/dl) in the men with a mean level of
40.53 (mg/dl) and ranged from 21.0 to 98.6
(mg/dl) in women with a mean level of 50.3
mg/dl (Table 2). With increasing body mass
index, the prevelance of low HDL had
signifcantly increased (p value <0.001) in
both men (p value= 0.011) and women (p
value <0.001). It was 0.7% among
underweigh, 12.8% among normal weight,
15.8% among overweight, and 22.1% among
obese (Table 2).
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Table (2): Prevalence of metabolic syndrome, metabolic abnormalites, and levels of HDL
according to NCEP-ATPIII definition.

Metabolic syndrome (MetS)

Men
n(%)
192(34.2)

Women
n(%)
174(33.2)

Total
n(%)
366(33.8)

0.707

Low high-density lipoproteins (HDL)

288(51.3)

272(51.8)

560(51.6)

0.876

High triglycerides
High blood pressure (BP)

220(39.3)
281(50.1)

129(24.6)
213(40.6)

349(32.2)
494(45.5)

<0.001
0.002

Increased waist circumferences (WC)
High fasting blood sugar (FBS)

167(29.8)
110(19.6)

233(42.3)
96(18.3)

390(35.9)
206(19.0)

<0.001
0.578

Body mass index (BMI) ≥25
Levels of HDL in mg/dl

374(67.1)

332(63.2)

706(65.2)

0.182

10-19.9

5(0.9)

0(0)

5(0.5)

20-29.9
30-39.9

62(11.1)
221(39.4)

25(4.8)
75(14.3)

87(8)
296(27.3)

40-49.9
50-59.9

192(34.2)
59(10.5)

176(33.5)
130(24.8)

368(33.9)
189(17.4)

≥60

22(3.9)

119(22.7)

141(13.0)

Mean ± SD
Classes of Body Mass Index

40.53±10.48

50.30±12.5

Under-weight
Normal-weight

2(0.4)
84(15.0)

6(1.1)
55(10.5)

8(0.74)
139(12.8)

Over-weight
Obese

98(17.5)
103(18.4)

74(14.1)
137(26.0)

172(15.8)
240(22.1)

Metabolic syndrome and metabolic abnormalities

P-value

Abbreviations: mg/dl: Milligrams Per Deciliter, HDL: High-Density Lipoproteins, SD: Standard Deviation
2.176, 95%CI (1.685-2.809)) were signifiUnivariate analysis of metabolic abnormalicantly associated with low HDL (p value
ties, lifestyle, and environmental risk factors
<0.001) (Table3). For lifestyle and environFor metabolic abnormalities factors, the
mental factors, the univariate analysis reunivariate analysis revealed that metabolic
vealed a significant association between low
syndrome (Odd ratio (OR, 10.79, 95% ConHDL and marital status for married (OR,
fidence Interval (CI) (7.78-14.9)) and all in2.183, 95%CI (1.695-2.817)), current tobacco
creased metabolic abnormalities including
smoking (OR, 1.704, 95%CI (1.269-2.289)),
triglycerides (OR, 4.284, 95%CI (3.23occupational exposure to pesticides (OR,
5.681)), high fasting blood sugar (OR, 2.145,
1.702, 95%CI (11.164-2.489)) (p value
95%CI (1.561-2.949)), high blood pressure
<0.001). Gender, alcohol intake, physical
(OR, 2.133, 95%CI (1.671-2.2721)), inactivity, and sedentary lifestyle had shown no
creased waist circumferences (OR, 2.506,
association with low HDL (Table 3).
95%CI (1.937-3.242)), and obesity (OR,
Table (3): Univariate analysis of metabolic abnormalities factors.
Metabolic abnormalities
Triglyceride
High
Normal
Blood pressure (BP)
High
Normal

N (%)

OR

95%(CI)

P-value

260(46.6)
298(53.4)

4.284

3.23-5.681

<0.001

305(54.4)
255(45.5)

2.133

1.671-2.2721

<0.001
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Metabolic abnormalities
Systolic blood pressure (SBP)
High
Normal
Diastolic blood pressure (DBP)
High
Normal
Waist circumferences (WC)
High
Normal
Fasting blood sugar (FBS)
High
Normal
Body mass index (BMI)
≥25
<25
Metabolic syndrome (MetS)
Yes
No
Social, life- style, and environmental factors
Gender
Male
Female
Marital status
Single
Married, divorced, widow
Current tobacco smoking
Yes
No
Alcohol intake
Yes
No
Exposure to occupational pesticide
Yes
No
Sleep>8 hours/day
Yes
No
Walk≥2 hours/day
Yes
No
Regular physical activity ≥5 times/week
Yes
No
Long sitting ≥4hours/day
Yes
No

N (%)

OR

95%(CI)

P-value

254(45.5)
304(54.4)

2.314

1.792-2.988

<0.001

196(35.1)
362(64.9)

1.823

1.395-2.388

<0.001

257(45.9)
303(54.1)

2.506

1.937-3.242

<0.001

137(24.5)
432(75.5)

2.145

1.561-2.949

<0.001

412(73.7)
147(26.3)

2.176

1.685-2.809

<0.001

311(55.7)
247(44.3)

10.78

7.78-14.93

<0.001

288(51.8)
272(48.6)

0.981

0.773-1.245

0.876

152(27.1)
408(72.9)

0.458

0.355-0.590

<0.001

147(27.4)
390(72.6)

1.704

1.269-2.289

<0.001

8(1.5)
526(98.5)

1.272

0.438-3.693

0.760

81(15.1)
456(84.9)

1.702

1.164-2.489

0.006

369(74.0)
139(26.0)

0.805

0.605-1.071

0.136

43(14.3)
258(85.9)

1.131

0.705-1.814

0.610

53(9.9)
484(90.1)

0.707

0.483-1.035

0.074

180(33.5)
357(66.5)

0.878

0.680-1.132

0.315

Abbreviations: OR: Odds Ratio, CI: Confident Interval
above-mentioned variables, the LogisticMultivariate logistic regression analysis
Regression Model identified only increased
The multivariate logistic regression
triglycerides (OR, 3.341, 95%CI (2.165model included all variables found to be sig5.155), p value <0.001)) and increased waist
nificant in the univariate analysis; increased
circumferences (OR, 1.841, 95%CI (1.200fasting blood sugar, increased serum triglyc2.825), p value=0.005)) to be significantly
erides, increased blood pressure, increased
associated with low HDL (Table 4).
waist circumferences, increased BMI, marital
status, tobacco smoking, and exposure to occupational pesticides. Controlling for all the
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Table (4): Logistic regression model of risk factors for low HDL.
Age

OR
1.001

95%(CI)
0.981-1.020

P-value
0.959

Triglycerides
High
3.341
2.165-5.155
<0.001
Normal
Reference group
Blood pressure (BP)
High
1.153
0.770-1.726
0.491
Normal
Reference group
Waist circumferences (WC)
High
1.841
1.200-2.825
0.005
Normal
Reference group
Fasting blood sugar (FBS)
High
1.038
0.612-1.759
0.890
Normal
Reference group
Marital status
Single
0.646
0.396-1.055
0.081
Married, divorced, widow
Reference group
Tobacco smoking
Yes
1.0304
0.859-1.980
0.212
No
Reference group
Exposure to occupational pesticide
Yes
1.017
0.606-1.707
0.948
No
Reference group
Walk≥2 hours/day
Yes
1.118
0.666-1.876
0.672
No
Reference group
Address
City
0.496
0.242-1.019
0.56
Village
0.404
0.404-0.200
0.011
Camps
Reference group
*reference category is participants with normal HDL
Abbreviations: OR: Odds Ratio, CI: Confident Interval
ticipants with low HDL had MetS. A previDISCUSSION
ous study was conducted in Gaza StripThe results of this study had revealed
Palestine affirmed that 98% of low HDL
that the prevalence of low HDL was high
population with type 2 diabetes are diagnosed
among adult Palestinians (51.5%) in both
with MetS [46]. These results outweigh the
men and women with no gender differences.
prevalence of low HDL among MetS patients
Low HDL is shown to be a key component in
worldwide [47-49].
the prediction of cardiovascular disease risk
The univariate analysis revealed that low
and may trigger the pathogenesis of metabolHDL was highly associated with metabolic
ic syndrome [13, 14]. It carries the strongest
abnormalities, which is consistent with other
risk in predicting the development of metastudies [15, 35, 36, 39, 42, 50]. Nonbolic syndrome and might directly affect glucommunicable diseases including cardiovascose metabolism [15, 43, 44]. Metabolic syncular diseases and diabetes have become the
drome has also been demonstrated as a comleading causes of mortality and morbidity
mon precursor to the development of diabetes
among Palestinians. They have resulted in
mellitus (DM) and cardiovascular diseases
substantial direct morbidity and mortality in
[45]. In this study, the prevalence of metaboloccupied Palestinian territories [51]. The
ic syndrome was high and strongly associated
prevalence of diabetes was estimated to be
with low HDL levels. Therefore, the results
high (15.3%) among Palestinians compared
of this study indicate that at least half of the
to a worldwide prevalence (6%) [52]. Cardiac
adult Palestinian population could be at risk
disease was reported to be the number one
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cause of death in the occupied Palestinian
territories, accounting for 21.0% of all
deaths. Hypertension was ranked eighth and
accounting for about 5% of all deaths [53].
Therefore, low HDL, as well as metabolic
syndrome, are increasingly becoming a challenging public health issue in Palestine
[51]. The low HDL and its many consequences, including metabolic syndrome will
continue to increase unless we can find a way
to prevent obesity and metabolic syndrome in
adults.
Although decreased HDL had increased
with increasing BMI and metabolic abnormalities, it was also highly prevalent among
normal-weight adults indicating that other
factors could influence low HDL among Palestinians. This line of results takes on added
importance because these individuals are frequently undetected and undiagnosed because
of their normal BMI. This also indicates that
low HDL level is becoming an increasingly
prominent feature not only in MetS patients
but also in general population. Therefore,
screening in individuals with a normal BMI
is important in preventing diabetes and cardiovascular diseases. Action should be taken to
prevent and therefore, to slow the rise of
metabolic abnormalities. If no action is taken
to reduce these abnormalities, they will become an increasing burden for the health system.
It is known that levels of HDL are modifiable through behavioral factors including
diet, physical activity, alcohol intake, smoking, and exposure to pesticides [20, 23, 54].
In terms of risk factors, the univariate analysis revealed that tobacco smoking, occupational exposure to pesticides, and being married were associated with low HDL. It has
also been demonstrated previously that smoking cessation is associated with an up to 10%
increase in HDL level [55]. Moreover, low
HDL is more prevalent among married than
single men and women [46, 49, 56]. These
factors of low HDL level are attractive targets for approaches to increase HDL. It can
increase through several lifestyle changes.
The most important among these are smoking
cessation and increased physical activity especially in those who are obese and overweight [57]. It was estimated that for every 1
kg of weight loss, serum HDL increases by

0.35 mg/dl [58, 59]. Therefore, none pharmacologic approaches that can effectively increase serum levels of HDL including weight
control, specific nutritional choices, exercise,
and smoking cessation should be adapted
[59].
By using logistic regression analysis, only dyslipidemia and central obesity remained
independent risk factors for low HDL. This
agrees with previous studies which indicated
that central obesity increases with age and is
more frequent in women; the higher the central obesity, the lower the concentration of
HDL [60]. These results also agree with other
studies that revealed no association with
HDL levels and blood pressure [61].
Dyslipidemias were reported to be strongly
associated with low HDL, metabolic syndrome and thus CVD [62, 63]. The high
prevalence and disease burden of elevated
serum triglyceride and central obesity highlight the need for implementation of multicomponent interventions to reduce the prevalence and disease burden of these abnormalities. More research investigating factors associated with dyslipidemia among Palestinians is recommended.
Many studies showed that those who are
genetically predisposed to have low HDL
levels have HDL in the range of less than 30
mg/dl [64-67]. Only 16% of the participants
were with HDL levels less than 30 mg/dl and
they were more likely to be men, obese and
aged 40 years or more. Genetic factors were
not investigated directly in this study and
thus, further genetic studies for low HDL are
recommended. We also recommend spending
more efforts in developing targeting preventive interventions and awareness campaigns
for key risk factors for non-communicable
diseases. Moreover, we recommend further
studies to be conducted in different areas in
the West Bank. Finally, we recommend genetic studies to be conducted for dyslipidemia. In light of higher rates of overweight, obesity, central obesity, and metabolic abnormalities in adults, more research is needed for the
south of the West Bank. We recommend
screening adults using increased waist circumference.
Limitations
Even though the strength of this study is
its large scale was 1082 participants, this
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study has some limitations. Genetic factors
were not investigated. Ongoing research to
investigate genetic factors was established.
Another possible limitation is that we were
not able to assess the diet as a risk factor.
Further studies are needed in this area.
Conclusion
The prevalence of low HDL and metabolic syndrome was high. Although low
HDL had increased with increasing body
mass index and metabolic abnormalities, it
was also highly prevalent among underweight and normal-weight adults indicating
that other factors could influence decreased
HDL among Palestinians. This study found
higher than what anticipated prevalence of
low HDL in normal-weight adults. Action
should be taken to prevent and therefore, to
slow the rise of preventable noncommunicable diseases such as obesity, diabetes, hypertension, and dyslipidemia and
thus, cardiovascular diseases. If no action is
taken to reduce these diseases, these diseases
will become an increasing burden for the
health system. The results of this study have
important clinical implications for screening
adults using increased waist circumference.
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